SGS. M. Gardiner

S. M. Gardiner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


S. M. Gardiner has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • T Bennett

    School of Biomedical Sciences, University of Nottingham, Nottingham, UK

    14 shared publications
  • T. Bennett

    And Medicine School of Biomedical Sciences Queen's Medical Centre Centre for Integrated Systems Biology University of Nottingham Medical School Nottingham United Kingdom

    9 shared publications
  • P. A. Kemp

    6 shared publications
  • J. E. March

    5 shared publications
  • J E March

    Centre for Integrated Systems Biology and Medicine, School of Biomedical Sciences, Queens Medical Centre, University of Nottingham Medical School Nottingham, UK

    4 shared publications
  • P A Kemp

    Centre for Integrated Systems Biology and Medicine, School of Biomedical Sciences, Queens Medical Centre, University of Nottingham Medical School Nottingham, UK

    4 shared publications

Latest Publications

  • Open Access

    Possible involvement of GLP‐1(9–36) in the regional haemodynamic effects of GLP‐1(7–36) in conscious rats

    by Sm Gardiner, Je March, Pa Kemp, T Bennett, Dj Baker

    BACKGROUND AND PURPOSE The incretin hormone, glucagon‐like peptide (GLP)‐1(7–36), is rapidly cleaved by dipeptidyl peptidase 4 (DPP‐4) into GLP‐1(9–36), and although it is agreed that most, if not all, of the metabolic effects are attributable to the intact peptide, the degree to which the cardiovascular effects are due to the cleavage product is unclear. The purpose of this study was to measure the regional haemodynamic effects of GLP‐1(7–36), and determine the extent to which the cardiovascular effects of GLP‐1(7–36) were influenced by DPP‐4 inhibition and reproduced by GLP‐1(9–36). Additional experiments investigated the involvement of autonomic mechanisms in the cardiovascular effects of GLP‐1(7–36).EXPERIMENTAL APPROACH Regional haemodynamic effects of bolus doses and 4 h infusions of GLP‐1(7–36) amide and GLP‐1(9–36) amide were measured in conscious, chronically instrumented rats; the influence of DPP‐4 inhibition and autonomic blockade on responses to GLP‐1(7–36) were also assessed.KEY RESULTS Glucagon‐like peptide‐1(7–36) had clear regional haemodynamic effects comprising tachycardia, a rise in blood pressure, renal and mesenteric vasoconstriction and hindquarters vasodilatation, whereas GLP‐1(9–36) was devoid of any cardiovascular actions. The effects of GLP‐1(7–36) were enhanced by DPP‐4 inhibition, and the tachycardia and hindquarters vasodilatation were β‐adrenoceptor‐mediated.CONCLUSIONS AND IMPLICATIONS In conscious rats, the cardiovascular effects of GLP‐1(7–36) resemble those of the GLP analogue, exendin‐4, and are attributable to the intact peptide rather than the cleavage product, GLP‐1(9–36).


  • Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats

    by L Jolly, Je March, Pa Kemp, T Bennett, Sm Gardiner

    Background and purpose: Intermedin (IMD) is a newly identified member of the calcitonin family of peptides that shares structural and functional homology with adrenomedullin (AM).In vivocardiovascular effects of AM have been described, but relatively little is known of thein vivoactions of IMD. The purpose of this study was to compare the regional haemodynamic effects of IMD with those of AM in conscious rats, and investigate possible underlying mechanisms.Experimental approach: Measurements of blood pressure, heart rate and renal, mesenteric and hindquarters haemodynamics were made in conscious, chronically‐instrumented rats.Key results: IMD caused tachycardia and vasodilatation in all three vascular beds, associated with modest hypotension. At an equimolar dose (1 nmol·kg−1), most of the cardiovascular effects of IMD were greater than those of AM. The AM receptor antagonist, AM22–52, was equally effective in attenuating the renal and mesenteric vasodilator effects of IMD (1 nmol·kg−1) and AM (3 nmol·kg−1), but inhibition of NO synthase was more effective at reducing the vasodilator effects of IMD than AM. Vascular KATPchannel blockade with U‐37883A did not inhibit the vasodilator effects of either peptide.Conclusions and implications: In vivo, the regional haemodynamic profile of IMD resembles that of AM, and some of the vasodilator effects of IMD are mediated by AM receptors and NO, but not by KATPchannels. The cardiovascular effects of AM have been implicated in various pathological conditions, but whether or not endogenous IMD fulfils a similar role remains to be determined.


  • Open Access

    Regional haemodynamic responses to adenosine receptor activation vary across time following lipopolysaccharide treatment in conscious rats

    by L Jolly, J E March, P A Kemp, T Bennett, S M Gardiner

    Background and purpose: Studies using adenosine receptor antagonists have shown that adenosine‐mediated vasodilatations play an important role in the maintenance of regional perfusion during sepsis, but it is unclear whether vascular sensitivity to adenosine is affected. Here, we assessed regional haemodynamic responses to adenosine agonists and antagonists in normal and lipopolysaccharide (LPS)‐treated rats to investigate a possible role for adenosine in the haemodynamic sequelae.Experimental approach: Male Sprague–Dawley rats were chronically instrumented with pulsed Doppler flow probes to measure regional haemodynamic responses to adenosine‐receptor agonists (adenosine, 2‐choloro‐N6‐cyclopentyladenosine (CCPA)) and antagonists (8‐phenyltheophylline (8‐PT), 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX)), at selected time points in control and LPS‐treated rats.Key results: The responses to 8‐PT were consistent with endogenous adenosine causing bradycardia, and renal and hindquarters vasodilatation in control rats, whereas in LPS‐treated rats, there was evidence for endogenous adenosine causing renal (at 1.5 h) and hindquarters (at 6 h) vasoconstriction. In control animals, exogenous adenosine caused hypotension, tachycardia and widespread vasodilatation, whereas in LPS‐treated rats, the adenosine‐induced renal (at 1.5 h) and hindquarters (at 6 h) vasodilatations were abolished. As enhanced A1receptor‐mediated vasoconstriction could explain the results in LPS‐treated rats, vascular responsiveness to a selective A1‐receptor agonist (CCPA) or antagonist (DPCPX) was assessed. There was no evidence for enhanced vasoconstrictor responsiveness to CCPA in LPS‐treated rats, but DPCPX caused renal vasodilatation, consistent with endogenous adenosine mediating renal vasoconstriction under these conditions.Conclusions and implications: The results show changes in adenosine receptor‐mediated cardiovascular effects in endotoxaemia that may have implications for the use of adenosine‐based therapies in sepsis.British Journal of Pharmacology(2008)154, 1600–1610; doi:10.1038/bjp.2008.205; published online 26 May 2008


  • Autonomic nervous system‐dependent and ‐independent cardiovascular effects of exendin‐4 infusion in conscious rats

    by S M Gardiner, J E March, P A Kemp, T Bennett

    Background and purpose: Glucagon‐like peptide‐1 (GLP) receptor agonists are promising therapeutic agents for the treatment of type II diabetes, but effects other than those on glucoregulation need assessing. Cardiovascular actions of bolus doses of the GLP receptor agonist exendin‐4 have been reported, but to date the effects of continuous infusions have not been described.Experimental approach: The regional haemodynamic effects and possible underlying mechanisms of 6 h infusions of exendin‐4 were measured in conscious, chronically instrumented rats.Key results: A 6 h infusion of exendin‐4 (up to 6 pmol kg−1 min−1) only modestly influenced blood pressure, but caused substantial, opposing, regionally selective vascular effects and tachycardia. A major involvement of β‐adrenoceptors in the vasodilator and cardiac effects was identified, with little or no direct contribution from α‐adrenoceptors to the vasoconstriction seen. Under conditions where α‐ and β‐adrenoceptors were antagonized, or when ganglionic transmission was blocked, a marked vasoconstrictor effect of exendin‐4 was revealed in the mesenteric and hindquarters vascular beds (about 50% fall in vascular conductances). No role for endogenous angiotensin II, vasopressin, endothelin, neuropeptide Y or prostanoids could be shown in these vasoconstrictor actions of exendin‐4.Conclusions and implications: The results show not only an important involvement of the autonomic nervous system in the cardiovascular actions of exendin‐4 infusion but also an underlying non‐autonomically mediated vasoconstrictor action, the mechanism of which remains to be identified.


  • Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats

    by A J Wheal, T Bennett, M D Randall, S M Gardiner

    Background and purpose: In anaesthetized spontaneously hypertensive rats (SHR), there is evidence for up‐regulation of cannabinoid (CB1) receptors: antagonism of CB1receptors causes a rise in blood pressure, and administration of the endocannabinoid, anandamide, or inhibition of anandamide degradation causes hypotension. These findings have led to the suggestion that the endocannabinoid system may be a therapeutic target in hypertension. However, since the cardiovascular responses to cannabinoids are substantially influenced by anaesthesia, the purpose of this study was to assess regional haemodynamic responses to cannabinoid receptor stimulation and inhibition in conscious SHR.Experimental approach: Cardiovascular responses to i.v. administration of anandamide, the cannabinoid receptor agonist, WIN 55212‐2, and the CB1receptor antagonist, AM 251, were measured in male SHR, Wistar Kyoto rats and outbred Wistar rats, chronically instrumented for recording renal, mesenteric and hindquarters haemodynamics in the conscious, freely‐moving state.Key results: Hypotensive responses to anandamide and WIN 55212‐2 only occurred in SHR, but these were relatively modest and not associated with CB1receptor‐mediated vasodilatation. In SHR only, anandamide caused bradycardia, which was inhibited by AM 251. Furthermore, a pressor response to CB1receptor antagonism occurred only in SHR, but was not associated with vasoconstriction. Moreover, there was some evidence for CB1receptor‐mediated vasoconstrictor actions of anandamide in SHR, which was not seen in the normotensive strains.Conclusions and implications: The results are consistent with activation of CB1receptors in SHR by endogenous ligands exerting an antihypertensive effect, but the findings do not indicate enhanced CB1receptor‐mediated vasodilator mechanisms in SHR.British Journal of Pharmacology(2007)152, 717–724; doi:10.1038/sj.bjp.0707410; published online 13 August 2007


  • Open Access

    A Comparison between the Cardiovascular Actions of Urocortin 1 and Urocortin 2 (Stresscopin-Related Peptide) in Conscious Rats

    by S. M. Gardiner, J. E. March, P. A. Kemp, T. Bennett

    The aims of the study were, in conscious Sprague-Dawley rats, to compare the effects of stresscopin-related peptide (SRP) and urocortin (UCN) 1 on blood pressure, heart rate, and regional hemodynamics; to determine whether or not there were residual tachycardic effects of SRP or UCN1 after cardiac autonomic blockade; and to investigate a possible involvement of corticotropin releasing factor type 1 (CRF1) receptor-mediated histamine release in the vasodilator actions of UCN1. SRP and UCN1 (both at 3 nmol/kg i.v.) caused hypotension, tachycardia, and mesenteric and hindquarters vasodilatation, but the magnitude and/or duration of the effects of UCN1 were generally greater than those of SRP. Pretreatment with atropine plus propranolol abolished the tachycardic effects of SRP and UCN1, and, under those conditions, the hypotensive effect of SRP, but not that of UCN1, was enhanced, probably because the hindquarters vasodilator effect of the latter was also reduced. Pretreatment with mepyramine plus cimetidine had no effect on the hemodynamic actions of either SRP or UCN1. It is concluded that, in conscious rats, the tachycardic effects of SRP and UCN1 are due to autonomic nervous activation mainly through baroreflex mechanisms. There is no evidence for an involvement of CRF1 receptor-mediated histamine release in the vasodilator actions of UCN1, but a propranolol-sensitive hindquarters vasodilator action of UCN, but not of SRP, was identified.


  • Effects of chronic nitric oxide synthase inhibition on the cardiovascular responses to cannabinoids in vivo and in vitro

    by A J Wheal, T Bennett, M D Randall, S M Gardiner

    Since the vasorelaxant potency of the endocannabinoid anandamide is enhanced in perfused mesenteric vascular beds from rats made hypertensive by chronic inhibition of NO synthase (L-NAME in drinking water), we hypothesized that in vivo, anandamide-induced vasodilatation would be similarly enhanced in L-NAME-treated animals. Male Sprague-Dawley rats were given L-NAME in drinking water (7.5 mg kg(-1) day(-1)) for 4 weeks. Relaxant effects of anandamide were measured in perfused mesenteric vascular beds and in isolated small mesenteric arteries. Renal, mesenteric and hindquarters haemodynamic responses to anandamide, methanandamide, the synthetic cannabinoid agonist WIN-55212-2 and the cannabinoid receptor antagonist AM251 were assessed in conscious, chronically-instrumented rats. Vasorelaxant responses to anandamide were enhanced in the perfused mesentery but not in isolated mesenteric resistance vessels. In vivo, anandamide caused vasodilatation only in the hindquarters vascular bed and only in control rats. Methanandamide caused a late-onset (40 min after administration) tachycardia, mesenteric and hindquarters vasoconstriction, and renal vasodilatation, which did not differ between control and L-NAME-treated rats. AM251 had no effect on resting blood pressure in control or L-NAME-treated rats and WIN55212-2 caused pressor and renal and mesenteric vasoconstrictor responses, with hindquarters vasodilatation in both groups of animals. The results provide no in vivo evidence for enhanced vasodilator responses to cannabinoids, or up-regulation of endocannabinoids or their receptor activity, following chronic NO synthase inhibition.


  • Regional Hemodynamic Effects of Neutral Endopeptidase Inhibition and Angiotensin (AT1) Receptor Antagonism Alone or in Combination in Conscious Spontaneously Hypertensive Rats

    by S. M. Gardiner, J. E. March, P. A. Kemp, S. A. Ballard, T. Bennett

    We tested the hypothesis that angiotensin (AT1) receptor antagonism (with losartan) would enhance the cardiovascular actions of neutral endopeptidase (NEP) inhibition [with candoxatrilat or (2S)-2-{[1-({[(1S)-1-carboxy-2-(5-phenyl-1,3-oxazol-2-yl)ethyl]amino}carbonyl)cyclopentyl]methyl}-4-methoxybutanoic acid (UK-489,329)] in conscious spontaneously hypertensive rats (SHR). Four-day continuous intravenous infusion of candoxatrilat (1.9 μg kg-1 min-1) or UK-489,329 (0.15 μg kg-1 min-1) had no significant cardiovascular effects, whereas candoxatrilat (6.4 μg kg-1 min-1) had a modest antihypertensive effect (-10.9 mm Hg on day 4) but no significant sustained effects on regional hemodynamics. Losartan caused a fall in blood pressure (maximum -29.2 mm Hg on day 4) that was associated with renal, mesenteric, and, to a lesser extent, hindquarters vasodilatation. The combination of losartan with either dose of candoxatrilat had no greater antihypertensive or vasodilator effects than losartan alone, with the exception of the increase in renal vascular conductance, which was greater with the combination of the drugs than with either drug alone (significant only in the lower dose study). Losartan combined with UK-489,329 showed a greater antihypertensive effect than losartan alone (-14.6 mm Hg greater on day 4), although the effects of the combination were not significantly greater than the sum of the effects of both agents administered separately. However, losartan combined with UK-489,329 caused increases in renal and hindquarters vascular conductance that were significantly greater with the combination than with either agent given alone. Thus, in conscious SHR, the renin-angiotensin system may act to oppose a vasodilator action of NEP inhibition, particularly in the renal vascular bed.


  • Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation

    by Sheila M Gardiner, Julie E March, Philip A Kemp, Janet J Maguire, Rhoda E Kuc, Anthony P Davenport, Terence Bennett

    The aim of the study was to measure regional haemodynamic responses to 6 h infusions of human urotensin II (hUII), to identify possible mediators of the effects observed, and to relate the findings to the distribution of urotensin II receptors (UT receptors). Male, Sprague-Dawley rats had pulsed Doppler flow probes and intravascular catheters implanted for measurement of regional haemodynamics in the conscious, freely moving state. Infusions of saline (0.4 ml h(-1)) or hUII (30, 300 and 3,000 pmol kg(-1) h(-1)) were given i.v. for 6 h, and the effects of pretreatment with indomethacin (5 mg kg(-1) h(-1)), N(G)-nitro-L-arginine methyl ester (L-NAME, 3 mg kg(-1) h(-1)) or propranolol (1 mg kg(-1); 0.5 mg kg(-1) h(-1)) on responses to hUII (300 pmol kg(-1) h(-1) for 6 h) were assessed. Cellular localisation of UT receptor-like immunoreactivity was determined in relevant tissues. hUII caused dose-dependent tachycardia and hindquarters vasodilatation, accompanied by a slowly developing rise in blood pressure. Haemodynamic effects of hUII were attenuated by propranolol or L-NAME and abolished by indomethacin. UT receptor-like immunoreactivity was detected in skeletal and vascular smooth muscle. The findings indicate that in conscious rats, infusions of hUII cause vasodilatation, which, of the vascular beds monitored, is selective for the hindquarters and dependent on cyclooxygenase products and nitric oxide. The pressor effect of hUII under these conditions is likely to be due to an increase in cardiac output, possibly due to a positive inotropic effect. UT receptor-like immunoreactivity present in skeletal muscle is consistent with the haemodynamic pattern.